Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada

Inclusion Criteria: For Exposed vaccinated cohort: * Written informed consent, and assent in case of minors, obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject. * Aged between, and including, 15 and 25 years of age. * Residing within the US or Canada. * Subjects who received at least one dose of CERVARIX. * Gestational age at inclusion should be 19 completed weeks (i.e. 133 days of gestation) or less. * Last menstrual period between 30 days before and 90 days after any dose of CERVARIX with a maximum of 20% of subjects with last menstrual period between 46 and 90 days after any dose of CERVARIX. * Subjects who the Investigator believes can and will comply with the requirements of the protocol (e.g. available for phone interviews). Or subjects who the Investigator believes that parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol. For Non-exposed vaccinated cohort: * Written informed consent, and assent in case of minors, obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject. * Aged between, and including, 15 and 25 years of age. * Residing within the US or Canada. * Subjects who received at least one dose of CERVARIX or at least one dose of GARDASIL. * Gestational age at inclusion should be 19 completed weeks (i.e. 133 days of gestation) or less. * Last menstrual period between 120 days and 18 months after the last dose of CERVARIX/ GARDASIL. * Subjects who the Investigator believes can and will comply with the requirements of the protocol (e.g. available for phone interviews). Or subjects who the Investigator believes that parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol. Exclusion Criteria: For Exposed vaccinated cohort: * Last menstrual period between 30 days before and 90 days after any GARDASIL dose. * Ongoing pregnancy with foetus known to be non-viable. * Ongoing pregnancy with pre-enrolment knowledge by prenatal diagnosis of a major structural defect. * Use of any investigational or non-registered product (drug or vaccine) during the study period. For Non-exposed vaccinated cohort: * Ongoing pregnancy with foetus known to be non-viable. * Ongoing pregnancy with pre-enrolment knowledge by prenatal diagnosis of a major structural defect. * Use of any investigational or non-registered product (drug or vaccine) during the study period.